Inline Bioaerosol Reduction testing measures single-pass microbial aerosol reduction across in-duct, enclosed-flow, or device-mounted treatment systems under defined flow and load conditions. Controlled duct sections, bioaerosol generation, viable samplers, filter trains, airflow logging, and culture, qPCR, or droplet digital PCR (ddPCR) endpoints support ISO 17025 records and ASHRAE 241 aligned reduction metrics:
- In-duct HVAC air-cleaner comparison under ASHRAE 241 context, using defined flow, upstream/downstream samplers, and device-off baselines for single-pass reduction.
- UVGI or active-treatment module verification for building ventilation systems, using ASHRAE 62.1 airflow context, UV or mode logs, and viable recovery.
- Inline medical or scavenging interface screening under ISO 17025 controls, using sealed adapters, bioaerosol load control, and qPCR or ddPCR endpoint quantitation.
- ISO 16000 indoor-air duct studies for air-treatment products, using defined injection, downstream sampling, RH and temperature logging, and replicate condition blocks.
- EPA antimicrobial product performance support for air-treatment claims, using organism selection, device-off controls, recovery checks, and reduction metrics matched to claim language.
Use inline bioaerosol reduction testing when the decision depends on what the device removes in a single pass through a defined flow path. The protocol fixes flow, load, sampling interval, endpoint, and alignment frame before testing begins.